Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) released its earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14), Zacks reports. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The firm had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.75 million.
Xenetic Biosciences Trading Up 0.3 %
Shares of XBIO stock opened at $3.66 on Friday. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20. The business’s fifty day moving average is $3.89 and its 200 day moving average is $3.93.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a research note on Tuesday, August 20th.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Read More
- Five stocks we like better than Xenetic Biosciences
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Top-Performing Non-Leveraged ETFs This Year
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Stock Average Calculator
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
